Does the media prefer JNJ or EBS?

In the previous week, Johnson & Johnson had 86 more articles in the media than Emergent Biosolutions. MarketBeat recorded 93 mentions for Johnson & Johnson and 7 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.11 beat Emergent Biosolutions' score of 0.92 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 67 Very Positive mention(s) 11 Positive mention(s) 7 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Positive Emergent Biosolutions 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EBS or ABUS?

In the previous week, Arbutus Biopharma had 1 more articles in the media than Emergent Biosolutions. MarketBeat recorded 8 mentions for Arbutus Biopharma and 7 mentions for Emergent Biosolutions. Arbutus Biopharma's average media sentiment score of 1.19 beat Emergent Biosolutions' score of 0.92 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent Biosolutions 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LXRX or EBS?

In the previous week, Emergent Biosolutions had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 7 mentions for Emergent Biosolutions and 6 mentions for Lexicon Pharmaceuticals. Emergent Biosolutions' average media sentiment score of 0.92 beat Lexicon Pharmaceuticals' score of 0.44 indicating that Emergent Biosolutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Emergent Biosolutions 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EBS or CADL?

In the previous week, Emergent Biosolutions had 2 more articles in the media than Candel Therapeutics. MarketBeat recorded 7 mentions for Emergent Biosolutions and 5 mentions for Candel Therapeutics. Emergent Biosolutions' average media sentiment score of 0.92 beat Candel Therapeutics' score of 0.63 indicating that Emergent Biosolutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent Biosolutions 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SLDB or EBS?

In the previous week, Emergent Biosolutions had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 7 mentions for Emergent Biosolutions and 5 mentions for Solid Biosciences. Emergent Biosolutions' average media sentiment score of 0.92 beat Solid Biosciences' score of 0.92 indicating that Emergent Biosolutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Emergent Biosolutions 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Emergent Biosolutions (EBS) Competitors

$5.92 -0.02 (-0.34%)

As of 08/28/2026 03:58 PM Eastern

Compare

EBS vs. JNJ, ABUS, LXRX, CADL, and SLDB

Should you buy Emergent Biosolutions stock or one of its competitors? Emergent Biosolutions's main competitors and comparable companies include Johnson & Johnson (JNJ), Arbutus Biopharma (ABUS), Lexicon Pharmaceuticals (LXRX), Candel Therapeutics (CADL), and Solid Biosciences (SLDB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Emergent Biosolutions compare to Johnson & Johnson?

Johnson & Johnson (NYSE:JNJ) and Emergent Biosolutions (NYSE:EBS) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

In the previous week, Johnson & Johnson had 86 more articles in the media than Emergent Biosolutions. MarketBeat recorded 93 mentions for Johnson & Johnson and 7 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.11 beat Emergent Biosolutions' score of 0.92 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	67 Very Positive mention(s)	11 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Positive
Emergent Biosolutions	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Johnson & Johnson has a net margin of 21.48% compared to Emergent Biosolutions' net margin of -22.95%. Johnson & Johnson's return on equity of 32.42% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.48%	32.42%	13.35%
Emergent Biosolutions	-22.95%	16.35%	6.17%

Johnson & Johnson has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

Johnson & Johnson presently has a consensus price target of $268.22, suggesting a potential downside of 0.03%. Emergent Biosolutions has a consensus price target of $10.00, suggesting a potential upside of 68.92%. Given Emergent Biosolutions' higher probable upside, analysts plainly believe Emergent Biosolutions is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.86	$26.80B	$8.63	31.09
Emergent Biosolutions	$742.90M	0.41	$52.60M	-$3.55	N/A

Summary

Johnson & Johnson beats Emergent Biosolutions on 13 of the 17 factors compared between the two stocks.

How does Emergent Biosolutions compare to Arbutus Biopharma?

Emergent Biosolutions (NYSE:EBS) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Emergent Biosolutions has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

In the previous week, Arbutus Biopharma had 1 more articles in the media than Emergent Biosolutions. MarketBeat recorded 8 mentions for Arbutus Biopharma and 7 mentions for Emergent Biosolutions. Arbutus Biopharma's average media sentiment score of 1.19 beat Emergent Biosolutions' score of 0.92 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arbutus Biopharma	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Emergent Biosolutions currently has a consensus price target of $10.00, suggesting a potential upside of 68.92%. Arbutus Biopharma has a consensus price target of $5.00, suggesting a potential downside of 1.38%. Given Emergent Biosolutions' higher probable upside, research analysts plainly believe Emergent Biosolutions is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Arbutus Biopharma has a net margin of 84.22% compared to Emergent Biosolutions' net margin of -22.95%. Arbutus Biopharma's return on equity of 90.98% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-22.95%	16.35%	6.17%
Arbutus Biopharma	84.22%	90.98%	82.34%

Emergent Biosolutions has higher revenue and earnings than Arbutus Biopharma. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.41	$52.60M	-$3.55	N/A
Arbutus Biopharma	$14.08M	71.34	-$33.50M	$0.79	6.42

78.4% of Emergent Biosolutions shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 6.0% of Emergent Biosolutions shares are held by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Arbutus Biopharma beats Emergent Biosolutions on 10 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

Emergent Biosolutions has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$41.47M	24.57	-$50.34M	-$0.15	N/A
Emergent Biosolutions	$742.90M	0.41	$52.60M	-$3.55	N/A

In the previous week, Emergent Biosolutions had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 7 mentions for Emergent Biosolutions and 6 mentions for Lexicon Pharmaceuticals. Emergent Biosolutions' average media sentiment score of 0.92 beat Lexicon Pharmaceuticals' score of 0.44 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Emergent Biosolutions	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Emergent Biosolutions has a net margin of -22.95% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Emergent Biosolutions' return on equity of 16.35% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
Emergent Biosolutions	-22.95%	16.35%	6.17%

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Lexicon Pharmaceuticals currently has a consensus target price of $4.55, indicating a potential upside of 98.69%. Emergent Biosolutions has a consensus target price of $10.00, indicating a potential upside of 68.92%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Lexicon Pharmaceuticals is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Lexicon Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

Summary

Emergent Biosolutions beats Lexicon Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to Candel Therapeutics?

Emergent Biosolutions (NYSE:EBS) and Candel Therapeutics (NASDAQ:CADL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 6.0% of Emergent Biosolutions shares are owned by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Emergent Biosolutions had 2 more articles in the media than Candel Therapeutics. MarketBeat recorded 7 mentions for Emergent Biosolutions and 5 mentions for Candel Therapeutics. Emergent Biosolutions' average media sentiment score of 0.92 beat Candel Therapeutics' score of 0.63 indicating that Emergent Biosolutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Emergent Biosolutions has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.41	$52.60M	-$3.55	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A

Emergent Biosolutions has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.51, indicating that its stock price is 151% less volatile than the broader market.

Emergent Biosolutions presently has a consensus price target of $10.00, suggesting a potential upside of 68.92%. Candel Therapeutics has a consensus price target of $19.29, suggesting a potential upside of 47.56%. Given Emergent Biosolutions' higher probable upside, research analysts clearly believe Emergent Biosolutions is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Candel Therapeutics has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-22.95%	16.35%	6.17%
Candel Therapeutics	N/A	-76.98%	-48.50%

Summary

Emergent Biosolutions beats Candel Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Emergent Biosolutions compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Solid Biosciences presently has a consensus price target of $18.18, suggesting a potential upside of 86.10%. Emergent Biosolutions has a consensus price target of $10.00, suggesting a potential upside of 68.92%. Given Solid Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Solid Biosciences is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Emergent Biosolutions has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Emergent Biosolutions	$742.90M	0.41	$52.60M	-$3.55	N/A

In the previous week, Emergent Biosolutions had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 7 mentions for Emergent Biosolutions and 5 mentions for Solid Biosciences. Emergent Biosolutions' average media sentiment score of 0.92 beat Solid Biosciences' score of 0.92 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Emergent Biosolutions	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Solid Biosciences has a beta of 2.41, meaning that its stock price is 141% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

Solid Biosciences has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Emergent Biosolutions	-22.95%	16.35%	6.17%

Summary

Emergent Biosolutions beats Solid Biosciences on 8 of the 15 factors compared between the two stocks.

Get Emergent Biosolutions News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EBS vs. The Competition

Export

Metric	Emergent Biosolutions	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$303.02M	$3.93B	$7.21B	$24.18B
Dividend Yield	N/A	3.61%	2.54%	3.72%
P/E Ratio	-1.67	11.62	273.16	30.01
Price / Sales	0.41	1,371.16	629.76	20.38
Price / Cash	1.61	44.06	28.74	19.75
Price / Book	0.59	16.92	11.08	4.84
Net Income	$52.60M	-$22.74M	$3.48B	$1.07B
7 Day Performance	16.77%	-0.31%	0.13%	-0.32%
1 Month Performance	-18.54%	9.80%	7.08%	1.84%
1 Year Performance	-28.55%	55.66%	24.67%	13.37%

Emergent Biosolutions Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EBS Emergent Biosolutions	3.3981 of 5 stars	$5.92 -0.3%	$10.00 +68.9%	-28.5%	$303.02M	$742.90M	N/A	2,420
JNJ Johnson & Johnson	4.5731 of 5 stars	$273.11 +1.1%	$268.22 -1.8%	+51.5%	$651.25B	$97.93B	31.65	138,200	Trending News Ex-Dividend
ABUS Arbutus Biopharma	1.519 of 5 stars	$5.20 -0.2%	$5.00 -3.8%	+36.7%	$1.03B	$14.08M	6.58	90	Positive News Analyst Upgrade Buyback Announcement High Trading Volume
LXRX Lexicon Pharmaceuticals	1.726 of 5 stars	$2.32 +0.9%	$4.55 +96.1%	+108.2%	$1.02B	$41.47M	N/A	140
CADL Candel Therapeutics	2.9243 of 5 stars	$12.86 -2.1%	$19.29 +50.0%	+125.7%	$1.00B	N/A	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EBS) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, ABUS, LXRX, CADL, and SLDB

How does Emergent Biosolutions compare to Johnson & Johnson?

Summary

How does Emergent Biosolutions compare to Arbutus Biopharma?

Summary

How does Emergent Biosolutions compare to Lexicon Pharmaceuticals?

Summary

How does Emergent Biosolutions compare to Candel Therapeutics?

Summary

How does Emergent Biosolutions compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, ABUS, LXRX, CADL, and SLDB

How does Emergent Biosolutions compare to Johnson & Johnson?

Does the media prefer JNJ or EBS?

Is JNJ or EBS more profitable?

Which has more risk & volatility, JNJ or EBS?

Do analysts recommend JNJ or EBS?

Do insiders and institutionals hold more shares of JNJ or EBS?

Which has preferable valuation & earnings, JNJ or EBS?

Summary

How does Emergent Biosolutions compare to Arbutus Biopharma?

Which has more risk & volatility, EBS or ABUS?

Does the media refer more to EBS or ABUS?

Do analysts prefer EBS or ABUS?

Is EBS or ABUS more profitable?

Which has higher earnings & valuation, EBS or ABUS?

Do institutionals & insiders hold more shares of EBS or ABUS?

Summary

How does Emergent Biosolutions compare to Lexicon Pharmaceuticals?

Which has preferable valuation and earnings, LXRX or EBS?

Does the media prefer LXRX or EBS?

Is LXRX or EBS more profitable?

Do insiders and institutionals have more ownership in LXRX or EBS?

Do analysts rate LXRX or EBS?

Which has more risk and volatility, LXRX or EBS?

Summary

How does Emergent Biosolutions compare to Candel Therapeutics?

Do institutionals & insiders hold more shares of EBS or CADL?

Does the media refer more to EBS or CADL?

Which has stronger earnings & valuation, EBS or CADL?

Which has more risk and volatility, EBS or CADL?

Do analysts rate EBS or CADL?

Is EBS or CADL more profitable?

Summary

How does Emergent Biosolutions compare to Solid Biosciences?

Do analysts rate SLDB or EBS?

Which has better valuation & earnings, SLDB or EBS?

Does the media favor SLDB or EBS?

Do insiders and institutionals have more ownership in SLDB or EBS?

Which has more volatility & risk, SLDB or EBS?

Is SLDB or EBS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools